Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 7/20 | 0.68 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.68 |
| ▸ | SRC | P12931 | 2/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.68 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.68 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.68 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.68 |
| ▸ | TRPM2 | O94759 | 2/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.65 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.65 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.65 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.65 |
| ▸ | LDHA | P00338 | 1/20 | 0.65 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.65 |
| ▸ | FBP1 | P09467 | 1/20 | 0.65 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.65 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.65 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30903856 | 1.00 | P2RY1 (0.68) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL4945718 | 0.93 | P2RY1 (0.69) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL27695784 | 0.93 | P2RY1 (0.63) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL30051599 | 0.93 | P2RY1 (0.69) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Phosphate SCHEMBL11576227 | 0.90 | P2RY1 (0.69) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| Adenosine Phosphate SCHEMBL15670947 | 0.90 | P2RY1 (0.73) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL18423487 | 0.86 | P2RY1 (0.73) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL17148064 | 0.85 | P2RY1 (0.67) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL5063172 | 0.85 | P2RY1 (0.71) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 | |
| SCHEMBL1332848 | 0.84 | P2RY1 (0.81) | P2RY1P2RY2SRCSMN1; SMN2P2RX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293512-B2 | Polypeptide having activity of aminoacyl-tRNA synthetase and use thereof | RIKEN (JP) | 2012-10-23 | — | — | US | claimed |
| US-20120028330-A1 | POLYPEPTIDE HAVING ACTIVITY OF AMINOACYL-tRNA SYNTHETASE AND USE THEREOF | RIKEN (JP) | 2012-02-02 | — | — | US | claimed |
| US-20090226966-A1 | Polypeptide having activity of aminoacyl-tRNA synthetase and use thereof | RIKEN (JP) | 2009-09-10 | — | — | US | claimed |
| CN-119970725-A | Use of substituted isoxazol-5-one derivative | 河南省人民医院 | 2025-05-13 | — | — | CN | disclosed |
| US-20230279378-A1 | CHIMERIC THERMOSTABLE AMINOACYL-TRNA SYNTHETASE FOR ENHANCED UNNATURAL AMINO ACID INCORPORATION | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-09-07 | — | — | US | disclosed |
| EP-4045639-A1 | CHIMERIC THERMOSTABLE AMINOACYL-TRNA SYNTHETASE FOR ENHANCED UNNATURAL AMINO ACID INCORPORATION | Trustees of Boston College (US) | 2022-08-24 | — | — | EP | disclosed |
| CN-114555645-A | Chimeric thermostable aminoacyl tRNA synthetases for enhanced incorporation of unnatural amino acids | 波士顿学院董事会 | 2022-05-27 | — | — | CN | disclosed |
| CN-108658916-B | Substituent 6, 8-dimercapto-2-phenyl-4H-chromen-4-one derivative and preparation method and application thereof | 四川大学 | 2021-09-24 | — | — | CN | disclosed |
| WO-2021076795-A1 | CHIMERIC THERMOSTABLE AMINOACYL-TRNA SYNTHETASE FOR ENHANCED UNNATURAL AMINO ACID INCORPORATION | TRUSTEES OF BOSTON COLLEGE (US) | 2021-04-22 | — | — | WO | disclosed |
| CN-108658916-A | 6,8- dimercapto -2- phenyl -4H- chromen-4-one derivatives of substituent group and its preparation method and application | 四川大学 | 2018-10-16 | — | — | CN | disclosed |
| EP-2796546-B1 | Incorporation of unnatural amino acids | SCRIPPS RESEARCH INST (US) | 2017-08-09 | — | — | EP | disclosed |
| EP-1456360-A2 | METHODS AND COMPOSITION FOR THE PRODUCTION OF ORTHOGANAL TRNA-AMINOACYLTRNA SYNTHETASE PAIRS | The Scripps Research Institute (US) | 2004-09-15 | — | — | EP | disclosed |
| WO-2003091418-A2 | NOVEL ESSENTIAL FUNGAL POLYNUCLEOTIDES, POLYPEPTIDES, AND METHODS OF USE | BRISTOL-MYERS SQUIBB COMPANY (US) | 2003-11-06 | — | — | WO | disclosed |
| US-6631329-B1 | Complexed with mupirocin and tRNAile; streak-seedingm vapor equilibrating; replacing with cryoprotectant; flash-freezing | YALE UNIVERSITY | 2003-10-07 | — | — | US | disclosed |
| US-20030108885-A1 | Comprises ribonuclease barnase marker gene; recombination/genetic engineering; libraries; drug resistance | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-06-12 | — | — | US | disclosed |
| US-20030082575-A1 | Translation system for use in the generation of protein containing adjusted amino acid sequences | THE SCRIPPS RESEARCH INSTITUTE (US) | 2003-05-01 | — | — | US | disclosed |
| WO-2002086075-A2 | METHODS AND COMPOSITION FOR THE PRODUCTION OF ORTHOGANAL TRNA-AMINOACYLTRNA SYNTHETASE PAIRS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-10-31 | — | — | WO | disclosed |
| WO-2002085923-A2 | IN VIVO INCORPORATION OF UNNATURAL AMINO ACIDS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2002-10-31 | — | — | WO | disclosed |
| EP-1200564-A2 | USE OF THE CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS ISOLEUCYL-tRNA SYNTHETASE IN ANTIBIOTIC DESIGN | YALE UNIVERSITY (US) | 2002-05-02 | — | — | EP | disclosed |
| WO-2001009154-A2 | USE OF THE CRYSTAL STRUCTURE OF STAPHYLOCOCCUS AUREUS ISOLEUCYL-tRNA SYNTHETASE IN ANTIBIOTIC DESIGN | YALE UNIVERSITY (US) | 2001-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030108885-A1 | Comprises ribonuclease barnase marker gene; recombination/genetic engineering; libraries; drug resistance | RNASEL, RNASEH1, RNASE1 | P2RY1 4740/4885P2RY2 4690/4885SRC 4566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.